<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04868604</url>
  </required_header>
  <id_info>
    <org_study_id>CLP05</org_study_id>
    <nct_id>NCT04868604</nct_id>
  </id_info>
  <brief_title>64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)</brief_title>
  <acronym>SECuRE</acronym>
  <official_title>A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clarity Pharmaceuticals Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clarity Pharmaceuticals Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in&#xD;
      participants with PSMA-expressing metastatic castrate resistant prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 11, 2021</start_date>
  <completion_date type="Anticipated">September 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2026</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This study is to be conducted in 3 phases, a dosimetry phase, a dose escalation phase and a cohort expansion phase.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biodistribution of 64Cu-SAR-bisPSMA</measure>
    <time_frame>48 hours</time_frame>
    <description>Biodistribution will be calculated by utilizing the PET/CT scans.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dosimetry of 64Cu-SAR-bisPSMA</measure>
    <time_frame>48 hours</time_frame>
    <description>Dosimetry will be calculated by utilizing the PET/CT scans.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modelling of 67Cu-SAR-bisPSMA dosimetry utilizing the 64Cu-SAR-bisPSMA PET/CT scans</measure>
    <time_frame>48 hours</time_frame>
    <description>Dosimetry will be calculated by utilizing the PET/CT scans.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose or Maximum Feasible Dose of a single dose of 67Cu-SAR-bisPSMA</measure>
    <time_frame>8 weeks</time_frame>
    <description>MDT as determined by cohort observations of DLTs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended dose of two doses of 67Cu-SAR-bisPSMA</measure>
    <time_frame>14 weeks</time_frame>
    <description>Recommended dose as determined by cohort observations of DLTs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of 67Cu-SAR-bisPSMA in terms of PSA response</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Proportion of participants with ≥50% decline in PSA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of 67Cu-SAR-bisPSMA in terms of radiographic response</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Efficacy will be assessed via the overall response rate according to RECIST V1.1 for soft tissue disease and according PCWG3 for bone lesions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of 67Cu-SAR-bisPSMA Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Adverse Events will be as assessed by CTCAE version 5.00</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of 67Cu-SAR-bisPSMA: Number of Participants With Changes from baseline in Vital Signs</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Change from baseline in vital signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of 67Cu-SAR-bisPSMA: Number of Participants With Changes from baseline in ECG parameters</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Change from baseline in ECG parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of 67Cu-SAR-bisPSMA: Number of Participants With Changes from baseline in laboratory results</measure>
    <time_frame>Up to 22 weeks</time_frame>
    <description>Change from baseline in laboratory results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of 64Cu-SAR-bisPSMA Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Adverse Events will be as assessed by CTCAE version 5.00</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Prostatic Neoplasms, Castration-Resistant</condition>
  <arm_group>
    <arm_group_label>67Cu-SAR-bisPSMA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the dosimetry phase patients will receive a single 200 MBq administration of 64Cu-SAR-bisPSMA.&#xD;
In the dose escalation phase patients will receive up to 2 administrations of 200 MBq of 64Cu-SAR-bisPSMA.&#xD;
In the cohort expansion phase patients will receive up to 3 administrations of 200 MBq of 64Cu-SAR-bisPSMA.&#xD;
In the dose escalation phase patients will receive up to 2 administrations of 67Cu-SAR-bisPSMA (dose will be determined based on cohort allocation).&#xD;
In the cohort expansion phase patients will receive 2 administrations of 67Cu-SAR-bisPSMA at the recommended dose level determined through dose escalation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>64Cu-SAR-bisPSMA</intervention_name>
    <description>64Cu-SAR-bisPSMA</description>
    <arm_group_label>67Cu-SAR-bisPSMA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>67Cu-SAR-bisPSMA</intervention_name>
    <description>67Cu-SAR-bisPSMA</description>
    <arm_group_label>67Cu-SAR-bisPSMA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent;&#xD;
&#xD;
          -  ≥18 years of age;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status of 0 to 2;&#xD;
&#xD;
          -  Life expectancy &gt;6 months;&#xD;
&#xD;
          -  Histological, pathological, and/or cytological confirmation of PCa;&#xD;
&#xD;
          -  Positive 64Cu-SAR-bisPSMA PET/CT scan, where 64Cu-SAR-bisPSMA uptake (standardized&#xD;
             uptake value [SUV] max) of at least 1 known lesion is higher than that of the liver on&#xD;
             the 1 hour positron emission tomography (PET)/computed tomography (CT) scan;&#xD;
&#xD;
          -  Castrate level of serum/plasma testosterone (&lt;50 ng/dL or &lt;1.7 nmol/L);&#xD;
&#xD;
          -  Have progressive mCRPC despite prior androgen deprivation therapy and at least either&#xD;
             enzalutamide and/or abiraterone (or other such androgen receptor pathway inhibitors).&#xD;
             Documented progressive mCRPC will be based on at least 1 of the following criteria:&#xD;
&#xD;
               1. Serum/plasma prostate specific antigen (PSA) progression defined as 2 consecutive&#xD;
                  increases in PSA over a previous reference value measured at least 1 week prior.&#xD;
                  The minimal value for study enrollment is 2.0 ng/mL;&#xD;
&#xD;
               2. Soft-tissue progression defined as a ≥20% increase in the sum of the diameter&#xD;
                  (SOD) (short axis for nodal lesions and long axis for non-nodal lesions) of all&#xD;
                  target lesions based on the smallest SOD since the last treatment directed at the&#xD;
                  metastatic cancer has started (not including hormonal therapy) or the appearance&#xD;
                  of 1 or more new lesions;&#xD;
&#xD;
               3. Progression of bone disease: evaluable disease or new bone lesions(s) by bone&#xD;
                  scan.&#xD;
&#xD;
          -  ≥1 metastatic lesion that is present at screening CT, magnetic resonance imaging&#xD;
             (MRI), or bone scan imaging obtained ≤28 days prior to enrollment into the study;&#xD;
&#xD;
          -  Participants must have recovered to ≤ Grade 2 from all clinically significant&#xD;
             toxicities related to prior therapies (prior chemotherapy, radiation, immunotherapy,&#xD;
             etc.);&#xD;
&#xD;
          -  Participants must have adequate organ function:&#xD;
&#xD;
               -  Bone marrow reserve:&#xD;
&#xD;
                    -  White blood cell (WBC) count ≥2.5 x 109/L (2.5 x 109/L is equivalent to 2.5&#xD;
                       x 103/μL and 2.5 x K/μL and 2.5 x 103/cc and 2500/μL) OR&#xD;
&#xD;
                    -  Absolute neutrophil count (ANC) ≥1.5 x 109 /L (1.5 x 109 /L is equivalent to&#xD;
                       1.5 x 103 /μL and 1.5 x K/μL and 1.5 x 103 /cc and 1500/μL);&#xD;
&#xD;
               -  Platelets ≥100 x 109 /L (100 x 109 /L is equivalent to 100 x 103 /μL and 100 x&#xD;
                  K/μL and 100 x 103 /cc and 100,000/μL);&#xD;
&#xD;
               -  Hemoglobin ≥9 g/dL (5.59 mmol/L);&#xD;
&#xD;
               -  Total bilirubin ≤1.5 x the institutional upper limit of normal (ULN). For&#xD;
                  participants with known Gilbert's Syndrome ≤3 x ULN is permitted;&#xD;
&#xD;
               -  Alanine aminotransferase or aspartate aminotransferase ≤3.0 x ULN OR ≤5.0 x ULN&#xD;
                  for participants with liver metastases;&#xD;
&#xD;
               -  Creatinine clearance or estimated glomerular filtration rate ≥50 mL/min&#xD;
&#xD;
          -  For participants who are human immunodeficiency virus infected: Participant must be&#xD;
             healthy and have a low risk of Acquired Immune Deficiency Syndrome related outcomes in&#xD;
             the opinion of the Investigator;&#xD;
&#xD;
          -  For participants who have partners of childbearing potential: Partner and/or&#xD;
             participant must use a method of birth control with adequate barrier protection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major surgery within 12 weeks prior to enrollment into the study;&#xD;
&#xD;
          -  Brain metastasis;&#xD;
&#xD;
          -  Histologic diagnosis of small cell or neuroendocrine prostate cancer;&#xD;
&#xD;
          -  Prior history of leukemia or Myelodysplastic Syndrome;&#xD;
&#xD;
          -  Diagnosis of Deep Vein Thrombosis or Pulmonary Embolism within 4 weeks prior to&#xD;
             enrollment into the study;&#xD;
&#xD;
          -  Unmanageable urinary tract obstruction;&#xD;
&#xD;
          -  Evidence of progressive lesion(s) on MRI and/or CT (&gt; 1 cm in mean diameter) that is&#xD;
             prostate-specific membrane antigen (PSMA) negative on the 1 hour 64Cu-SAR-bisPSMA&#xD;
             PET/CT scan as determined at screening;&#xD;
&#xD;
          -  Previous treatment with any systemic radionuclide (e.g. 177Lu, Strontium-89,&#xD;
             Samarium-153, Rhenium-186, Rhenium-188, Actinium-225, Radium-223, Iodine-131) within 6&#xD;
             months of treatment initiation;&#xD;
&#xD;
          -  Previous treatment with any systemic anti-cancer therapy (e.g. chemotherapy,&#xD;
             immunotherapy or biological therapy [including monoclonal antibodies]) within 4 weeks&#xD;
             prior to treatment on study with the exception of Luteinizing Hormone Releasing&#xD;
             Hormone, any other androgen deprivation therapy (ADT) (if ADT is discontinued prior to&#xD;
             enrolment, 14 days must elapse after abiraterone discontinuation and 28 days after&#xD;
             enzalutamide before participant can be enrolled) or low dose corticosteroids;&#xD;
&#xD;
          -  Previous treatment with any investigational agents within 4 weeks prior enrollment&#xD;
             into the study;&#xD;
&#xD;
          -  Known hypersensitivity to the components of the investigational products or its&#xD;
             analogues;&#xD;
&#xD;
          -  Transfusion for the sole purpose of making a participant eligible for study inclusion;&#xD;
&#xD;
          -  Spinal metastasis with symptomatic cord compression, or clinical or radiologic&#xD;
             findings indicative of impending cord compression;&#xD;
&#xD;
          -  Concurrent serious medical conditions, including, but not limited to, New York Heart&#xD;
             Association class III or IV congestive heart failure, history of congenital prolonged&#xD;
             QT syndrome, uncontrolled infection, known active hepatitis B or C, or other&#xD;
             significant co-morbid conditions that in the opinion of the Investigator would impair&#xD;
             study participation or cooperation;&#xD;
&#xD;
          -  Diagnosed with other malignancies that are expected to alter life expectancy or may&#xD;
             interfere with disease assessment. However, participants with a prior history of&#xD;
             malignancy that has been adequately treated and who have been disease free for more&#xD;
             than 3 years are eligible, as are participants with adequately treated non-melanoma&#xD;
             skin cancer, superficial bladder cancer;&#xD;
&#xD;
          -  Any condition or personal situation that would pose an unacceptable radiation safety&#xD;
             risk (as per institution guidelines, state and/or national regulations) to the&#xD;
             participant or carer at the time of release following the completion of therapy (e.g.&#xD;
             uncontrolled urinary incontinence, high dependency care);&#xD;
&#xD;
          -  Participants in whom it is known that EBRT is scheduled after enrollment into the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clarity Pharmaceuticals</last_name>
    <phone>+61 (0) 2 9209 4037</phone>
    <email>clinicaltrials@claritypharmaceuticals.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alan Bryce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tulane Cancer Center, Tulane Medical School</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Oliver Sartor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Martin Pomper, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lilja Solnes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Geoffrey Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine at Barnes-Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Amir Iravani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GU Research Network</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luke Nordquist, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine at New York-Presbyterian</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Scott Tagawa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 15, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms, Castration-Resistant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

